GlassScriptPhysician profile
Louis Violi
NPI 1922002633
$5,595.56
in general payments reported to CMS, 2019-2025
34 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $962 · 2020: $140 · 2021: $16.24 · 2022: $449 · 2023: $1,383 · 2024: $1,223 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,028.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,074.63 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $719.19 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Harmony Biosciences LLC | $480.43 | 2022-2025 | Wakix |
| Grifols USA, LLC | $392.99 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $342.91 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.97 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $261.60 | 2021-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $232.76 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $224.53 | 2024-2025 | Lumryz |
| Regeneron Healthcare Solutions, INC. | $190.23 | 2019-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $168.68 | 2023-2025 | Acthar |
| Jazz Pharmaceuticals INC. | $139.75 | 2019-2025 | Xywav |
| Axsome Therapeutics, INC. | $136.21 | 2023-2025 | Sunosi |
| Mylan Specialty L.P. | $118.80 | 2019-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $112.00 | 2023-2024 | Glassia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $89.87 | 2019-2023 | |
| Electromed, INC. | $75.63 | 2022-2024 | Smartvest |
| Genentech USA, INC. | $52.90 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $49.58 | 2022-2023 | Uptravi, Opsumit |
| Resmed Corp | $48.15 | 2025 | |
| Astellas Pharma US INC | $43.84 | 2023 | Cresemba |
| Idorsia Pharmaceuticals US INC | $43.69 | 2022-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $41.37 | 2019 | |
| Verona Pharma, INC. | $39.12 | 2025 | Ohtuvayre |
| Tactile Systems Technology INC | $35.07 | 2025 | Nimbl, Flexitouch Plus |
| United Therapeutics Corporation | $33.78 | 2023-2025 | Remodulin, Orenitram, Tyvaso |
| Viatris Specialty LLC | $22.47 | 2025 | Yupelri |
| Sanofi Pasteur INC. | $20.07 | 2023 | |
| Azurity Pharmaceuticals, INC. | $16.67 | 2024 | Horizant |
| Merck Sharp & Dohme LLC | $15.95 | 2023 | |
| Lilly USA, LLC | $14.83 | 2025 | Zepbound |
| Abbvie INC. | $13.63 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.07 | 2024 | |
| Circassia INC. | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Violi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.